Clinical Trial Update: A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the efficacy and safety of SEP-363856 (ulotaront) in acutely psychotic participants with schizophrenia, and the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Schizophrenia | Phase 3 | Status: RECRUITING